In the immediate post-transplant period (typically within the first 6 weeks), insulin is often the preferred therapy to rapidly control hyperglycemia and provide β-cell rest, a strategy that may help reduce the risk of persistent dysglycemia. Here, INS is linked to Hyperglycemia.